2025 Global Age-Related Mascular Degeneration Revenue Opportunities Report
Description
The 2025 Global Age-Related Mascular Degeneration Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Age-related Mascular Degeneration by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the global Age-Related Macular Degeneration (AMD) market are F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, and Regeneron Pharmaceuticals Inc. These companies dominate the market through their extensive portfolios of anti-VEGF therapies and innovative treatment approaches. Roche markets Vabysmo and Lucentis, capturing large revenue shares primarily in North America, especially the United States. Novartis is well known for products like Lucentis, while Bayer has secured regulatory approvals for Eylea 8 mg in China, offering long-lasting treatment options. Regeneron leads with Eylea, generating significant revenue from the US market.
Together, these companies hold roughly 85% of the global AMD treatment market share, reflecting their critical role in the evolving therapeutics landscape. Their strategies include continuous research and development, pipeline expansion, and regulatory approvals in major regions such as North America, Europe, and Asia-Pacific. They also engage in partnerships and acquisitions to enhance their technological capabilities and product offerings. This market leadership is bolstered by demographics, including aging populations and growing disease prevalence worldwide, driving increased demand for advanced, durable AMD therapies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Age-related Mascular Degeneration by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the global Age-Related Macular Degeneration (AMD) market are F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, and Regeneron Pharmaceuticals Inc. These companies dominate the market through their extensive portfolios of anti-VEGF therapies and innovative treatment approaches. Roche markets Vabysmo and Lucentis, capturing large revenue shares primarily in North America, especially the United States. Novartis is well known for products like Lucentis, while Bayer has secured regulatory approvals for Eylea 8 mg in China, offering long-lasting treatment options. Regeneron leads with Eylea, generating significant revenue from the US market.
Together, these companies hold roughly 85% of the global AMD treatment market share, reflecting their critical role in the evolving therapeutics landscape. Their strategies include continuous research and development, pipeline expansion, and regulatory approvals in major regions such as North America, Europe, and Asia-Pacific. They also engage in partnerships and acquisitions to enhance their technological capabilities and product offerings. This market leadership is bolstered by demographics, including aging populations and growing disease prevalence worldwide, driving increased demand for advanced, durable AMD therapies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
